
Opinion|Videos|May 28, 2025
Current Challenges in the Management of Bronchiectasis
Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of breath–predominant presentations.
Advertisement
Episodes in this series

Clinical Brief: Challenges in Managing Heterogeneous Bronchiectasis Presentations
Main Discussion Topics
- Bronchiectasis presents heterogeneously in symptoms, etiology, and severity.
- Treatment approaches should be tailored to specific phenotypes.
- Different symptom presentations require different management priorities.
Key Points for Physicians
- Recognize common symptom phenotypes:
- Cough predominant: focus on airway clearance techniques
- Dyspnea predominant with minimal cough: emphasize exercise, nutrition, and pulmonary rehabilitation
- Frequent exacerbator: targeted antibiotic strategies and infection prevention
- Perform thorough diagnostic workup to identify underlying etiologies.
- Treat comorbidities such as reflux, aspiration, and sinus disease.
- Apply a “treatable traits” approach focusing on specific characteristics rather than using a one-size-fits-all strategy.
Notable Insights
The heterogeneity of bronchiectasis necessitates precision medicine approaches tailored to individual patient presentations rather than standardized treatment algorithms.
Clinical Significance
Recognizing and addressing the varied presentations of bronchiectasis through phenotype-specific approaches improves management outcomes and patient quality of life.
Advertisement
Related to this article

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.

Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Elagolix Noninferior to Dienogest for Endometriosis Pain in Phase 3 Trial
3
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
4
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
5

